Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...